Every 10-Q that Intuitive Surgical Inc. (ISRG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ISRG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ISRG filings page.
Intuitive Surgical, Inc. reported strong first‑quarter 2026 growth, with revenue rising to $2.77 billion from $2.25 billion a year earlier, driven by higher product and service sales in both U.S. and international markets. Net income attributable to Intuitive increased to $821.5 million, and diluted EPS rose to $2.28 from $1.92, as gross profit expanded to $1.83 billion.
Operating income reached $855.3 million despite higher selling, general and administrative and research and development expenses, reflecting continued investment in growth. Cash flow from operations was strong at $911.9 million, supporting an active capital deployment program including a $533.1 million cash acquisition of European da Vinci and Ion distributors and $1.13 billion of share repurchases at an average price of $489.55 per share.
The company ended the quarter with total assets of $20.11 billion, including $7.98 billion of cash and investments, and stockholders’ equity of $17.60 billion. Management highlighted macroeconomic risks, evolving tariff and trade regimes, and ongoing litigation but noted that credit losses and hedge ineffectiveness remained immaterial in the period.
Intuitive Surgical (ISRG) reported strong Q3 2025 results. Revenue rose to $2,505.1M from $2,038.1M a year ago, led by instruments and accessories $1,518.8M, systems $590.4M, and service $395.9M. Net income was $704.4M with diluted EPS of $1.95 (vs. $1.56), and income from operations reached $759.7M. U.S. revenue was $1,717.6M; outside the U.S. was $787.5M.
Cash and cash equivalents were $2,806.6M and short‑term investments $2,102.2M as of September 30, 2025. Year‑to‑date cash from operations was $2,138.0M. The company repurchased $1,919.6M of stock in Q3 at an average price of $479.60; authorization remaining was about $1.9B. Remaining performance obligations were $2.88B. Intuitive outlined a pending acquisition of da Vinci and Ion distribution businesses in Italy, Spain, Portugal, Malta, and San Marino for EUR 290M upfront plus up to EUR 31M in milestones, subject to approvals and expected in the first half of 2026.
Legal updates included an appeals court affirming a prior judgment in the Rex Medical matter and a trial court ruling in Intuitive’s favor on SIS antitrust claims; a related class action was certified, with no trial date set.